Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for advancements in risk assessment and management strategies. Although significant progress has been made recently, identifying and managing apparently healthy individuals at a higher risk of developing atherosclerosis and those with subclinical atherosclerosis still poses significant challenges. Traditional risk assessment tools have limitations in accurately predicting future events and fail to encompass the complexity of the atherosclerosis trajectory. In this review, we describe novel approaches in biomarkers, genetics, advanced imaging techniques, and artificial intelligence that have emerged to address this gap. Moreover, polygenic risk scores and imaging modalities such as coronary artery calcium scoring, and coronary computed tomography angiography offer promising avenues for enhancing primary cardiovascular risk stratification and personalised intervention strategies. On the other hand, interventions aiming against atherosclerosis development or promoting plaque regression have gained attention in primary ASCVD prevention. Therefore, the potential role of drugs like statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, omega-3 fatty acids, antihypertensive agents, as well as glucose-lowering and anti-inflammatory drugs are also discussed. Since findings regarding the efficacy of these interventions vary, further research is still required to elucidate their mechanisms of action, optimize treatment regimens, and determine their long-term effects on ASCVD outcomes. In conclusion, advancements in strategies addressing atherosclerosis prevention and plaque regression present promising avenues for enhancing primary ASCVD prevention through personalised approaches tailored to individual risk profiles. Nevertheless, ongoing research efforts are imperative to refine these strategies further and maximise their effectiveness in safeguarding cardiovascular health.

Advancements in risk stratification and management strategies in primary cardiovascular prevention / F. Barkas, Y.Z. Sener, P.A. Golforoush, A. Kheirkhah, E. Rodriguez-Sanchez, J. Novak, M. Apellaniz-Ruiz, R.K. Akyea, V. Bianconi, A. Ceasovschih, Y.J. Chee, M. Cherska, J.R. Chora, M. D'Oria, N. Demikhova, D. Kocyigit Burunkaya, A. Rimbert, C. Macchi, K. Rathod, L. Roth, V. Sukhorukov, S. Stoica, R. Scicali, T. Storozhenko, J. Uzokov, M.G. Lupo, E.P.C. Van Der Vorst, F. Porsch. - In: ATHEROSCLEROSIS. - ISSN 0021-9150. - 395:(2024 Aug), pp. 117579.1-117579.14. [10.1016/j.atherosclerosis.2024.117579]

Advancements in risk stratification and management strategies in primary cardiovascular prevention

C. Macchi
Writing – Review & Editing
;
2024

Abstract

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for advancements in risk assessment and management strategies. Although significant progress has been made recently, identifying and managing apparently healthy individuals at a higher risk of developing atherosclerosis and those with subclinical atherosclerosis still poses significant challenges. Traditional risk assessment tools have limitations in accurately predicting future events and fail to encompass the complexity of the atherosclerosis trajectory. In this review, we describe novel approaches in biomarkers, genetics, advanced imaging techniques, and artificial intelligence that have emerged to address this gap. Moreover, polygenic risk scores and imaging modalities such as coronary artery calcium scoring, and coronary computed tomography angiography offer promising avenues for enhancing primary cardiovascular risk stratification and personalised intervention strategies. On the other hand, interventions aiming against atherosclerosis development or promoting plaque regression have gained attention in primary ASCVD prevention. Therefore, the potential role of drugs like statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, omega-3 fatty acids, antihypertensive agents, as well as glucose-lowering and anti-inflammatory drugs are also discussed. Since findings regarding the efficacy of these interventions vary, further research is still required to elucidate their mechanisms of action, optimize treatment regimens, and determine their long-term effects on ASCVD outcomes. In conclusion, advancements in strategies addressing atherosclerosis prevention and plaque regression present promising avenues for enhancing primary ASCVD prevention through personalised approaches tailored to individual risk profiles. Nevertheless, ongoing research efforts are imperative to refine these strategies further and maximise their effectiveness in safeguarding cardiovascular health.
Atherosclerosis; Cardiovascular disease; Plaque regression; Primary prevention; Risk stratification
Settore MEDS-02/A - Patologia generale
   Junior Leader la Caixa Postdoctoral Fellowship Programme: Shaping the new generation of leaders in research
   JUNIOR LEADER
   European Commission
   Horizon 2020 Framework Programme
   847648

   Metaphase and interphase detection of recurring numerical and structural chromosome anomalies in malignant hemopathies using fluorescence in situ hybridization (FISH)
   Swiss National Science Foundation
   Projects
   45846
ago-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0021915024001394-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Licenza: Nessuna licenza
Dimensione 1.58 MB
Formato Adobe PDF
1.58 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1156844
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 27
  • OpenAlex ND
social impact